Belimumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Belimumab" in English language version.

refsWebsite

Global rank English rank

22web.archive.org

1^st place

17nih.gov

4^th place

14doi.org

2^nd place

4semanticscholar.org

11^th place

8^th place

3fda.gov

447^th place

338^th place

3clinicaltrials.gov

5,225^th place

4,062^nd place

2europa.eu

68^th place

117^th place

2unil.ch

9,112^th place

7,304^th place

2gsk.com

low place

2hgsi.com

low place

2nytimes.com

7^th place

1drugs.com

399^th place

333^rd place

1tga.gov.au

3,984^th place

2,622^nd place

1canada.ca

1,712^th place

1,063^rd place

1hopkinsarthritis.org

low place

1drugbank.ca

4,294^th place

6,357^th place

1newswire.ca

2,726^th place

1,608^th place

1thelancet.com

2,393^rd place

3,174^th place

1medpagetoday.com

9,274^th place

5,856^th place

1medscape.com

719^th place

636^th place

1the-rheumatologist.org

low place

1marketscreener.com

7,438^th place

5,529^th place

1yahoo.com

38^th place

40^th place

1nice.org.uk

3,258^th place

2,666^th place

canada.ca

health-products.canada.ca

"Benlysta Product information". Health Canada. 22 October 2009. Retrieved 17 March 2023.

clinicaltrials.gov

Clinical trial number NCT00071812 for "A Safety and Efficacy Study of LymphoStat-B (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis" at ClinicalTrials.gov.
"Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome (BELISS)". July 2012. Archived from the original on 18 October 2012. Retrieved 1 November 2012.
Clinical trial number NCT00642902 for "Atacicept in Multiple Sclerosis, Phase II" at ClinicalTrials.gov

doi.org

Bossen C, Schneider P (October 2006). "BAFF, APRIL and their receptors: structure, function and signaling" (PDF). Seminars in Immunology. 18 (5): 263–275. doi:10.1016/j.smim.2006.04.006. PMID 16914324.
Kaveri SV, Mouthon L, Bayry J (September 2010). "Basophils and nephritis in lupus". The New England Journal of Medicine. 363 (11): 1080–1082. doi:10.1056/NEJMcibr1006936. PMID 20825323.
Schneider P (June 2005). "The role of APRIL and BAFF in lymphocyte activation". Current Opinion in Immunology. 17 (3): 282–289. doi:10.1016/j.coi.2005.04.005. PMID 15886118.
Shu HB, Hu WH, Johnson H (May 1999). "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens". Journal of Leukocyte Biology. 65 (5): 680–683. doi:10.1002/jlb.65.5.680. PMID 10331498. S2CID 1498303.
Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, et al. (July 1999). "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator". Science. 285 (5425): 260–263. doi:10.1126/science.285.5425.260. PMID 10398604.
Crowley JE, Treml LS, Stadanlick JE, Carpenter E, Cancro MP (June 2005). "Homeostatic niche specification among naïve and activated B cells: a growing role for the BLyS family of receptors and ligands". Seminars in Immunology. 17 (3): 193–199. doi:10.1016/j.smim.2005.02.001. PMID 15826824.
Edwards BM, Barash SC, Main SH, Choi GH, Minter R, Ullrich S, et al. (November 2003). "The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS". Journal of Molecular Biology. 334 (1): 103–118. doi:10.1016/j.jmb.2003.09.054. PMID 14596803.
Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, et al. (November 2003). "Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator". Arthritis and Rheumatism. 48 (11): 3253–3265. doi:10.1002/art.11299. PMID 14613291.
Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. (BLISS-52 Study Group) (February 2011). "Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial". Lancet. 377 (9767): 721–731. doi:10.1016/S0140-6736(10)61354-2. PMID 21296403. S2CID 28952240. Archived from the original on 17 October 2012. Retrieved 31 October 2012.
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al. (BLISS-76 Study Group) (December 2011). "A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus". Arthritis and Rheumatism. 63 (12): 3918–3930. doi:10.1002/art.30613. PMC 5007058. PMID 22127708.
Lee YH, Song GG (January 2018). "Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials". Lupus. 27 (1): 112–119. doi:10.1177/0961203317713143. PMID 28592201. S2CID 26026994.
Hahn BH (April 2013). "Belimumab for systemic lupus erythematosus". The New England Journal of Medicine. 368 (16): 1528–1535. doi:10.1056/NEJMct1207259. PMID 23594005.
Vugmeyster Y, Seshasayee D, Chang W, Storn A, Howell K, Sa S, et al. (February 2006). "A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys". The American Journal of Pathology. 168 (2): 476–489. doi:10.2353/ajpath.2006.050600. PMC 1606502. PMID 16436662.
Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, et al. (ATAMS Study Group) (April 2014). "Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial". The Lancet. Neurology. 13 (4): 353–363. doi:10.1016/S1474-4422(14)70028-6. PMID 24613349. S2CID 38926361.

drugbank.ca

DrugBank DB08879

drugs.com

"Belimumab (Benlysta) Use During Pregnancy". Drugs.com. 5 February 2020. Archived from the original on 4 December 2020. Retrieved 29 July 2020.

europa.eu

ema.europa.eu

"Benlysta EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 25 October 2020. Retrieved 29 July 2020.
European Medicines Agency: Benlysta Summary of Product Characteristics Archived 18 June 2018 at the Wayback Machine

fda.gov

Summary Minutes of the Arthritis Advisory Committee Meeting November 16, 2010 Archived 4 March 2017 at the Wayback Machine U.S. Food and Drug Administration (FDA)
2010 Meeting Materials, Arthritis Advisory Committee Archived 29 March 2012 at the Wayback Machine U.S. Food and Drug Administration (FDA)
"FDA approves Benlysta to treat lupus" (Press release). U.S. Food and Drug Administration (FDA). 9 March 2011. Archived from the original on 11 March 2011.

gsk.com

"GlaxoSmithKline and Human Genome Sciences announce FDA approval of Benlysta (belimumab) for the treatment of systemic lupus erythematosus". GlaxoSmithKline. 9 March 2011. Archived from the original on 17 March 2011. Retrieved 11 March 2011.
"Benlysta granted Orphan Drug Designation by US FDA for the potential treatment of systemic sclerosis". GSK (Press release). Archived from the original on 9 February 2023. Retrieved 9 February 2023.

hgsi.com

"Benlysta (belimumab)". Human Genome Sciences. Archived from the original on 21 April 2011. Retrieved 11 March 2011.
"Human Genome Sciences And Glaxosmithkline Announce Initiation Of Phase 3 Clinical Trial Of Lymphostat-B In Systemic Lupus Erythematosus" (Press release). Human Genome Sciences. 13 February 2007. Archived from the original on 25 April 2011. Retrieved 11 March 2011.

hopkinsarthritis.org

Belimumab: The first drug to be FDA approved for the treatment of lupus since 1955 Archived 13 September 2021 at the Wayback Machine, By Rebecca Manno, Johns Hopkins Arthritis Center, 15 July 2011

marketscreener.com

"GSK Says Benlysta Granted Orphan Drug Designation By FDA". MarketScreener. February 2023. Archived from the original on 9 February 2023. Retrieved 9 February 2023.

medpagetoday.com

FDA Questions Safety, Efficacy of Belimumab Archived 3 March 2021 at the Wayback Machine, By Emily P. Walker, Washington Correspondent, MedPage Today, 12 November 2010

medscape.com

"Should Belimumab Have Been Approved? Stephen Paget, Medscape Rheumatology, Mar 24, 2011". Archived from the original on 16 November 2015. Retrieved 27 April 2013.

newswire.ca

"Benlysta now approved in Canada in addition to standard therapy for treatment of active lupus nephritis in adult patients" (Press release). GlaxoSmithKline. 30 July 2021. Retrieved 17 March 2023 – via Newswire.

nice.org.uk

NICE publishes draft guidance on belimumab for systemic lupus erythematosus Archived 12 September 2012 at the Wayback Machine, press release, 26 April 2012

nih.gov

pubmed.ncbi.nlm.nih.gov

Bossen C, Schneider P (October 2006). "BAFF, APRIL and their receptors: structure, function and signaling" (PDF). Seminars in Immunology. 18 (5): 263–275. doi:10.1016/j.smim.2006.04.006. PMID 16914324.
Kaveri SV, Mouthon L, Bayry J (September 2010). "Basophils and nephritis in lupus". The New England Journal of Medicine. 363 (11): 1080–1082. doi:10.1056/NEJMcibr1006936. PMID 20825323.
Schneider P (June 2005). "The role of APRIL and BAFF in lymphocyte activation". Current Opinion in Immunology. 17 (3): 282–289. doi:10.1016/j.coi.2005.04.005. PMID 15886118.
Shu HB, Hu WH, Johnson H (May 1999). "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens". Journal of Leukocyte Biology. 65 (5): 680–683. doi:10.1002/jlb.65.5.680. PMID 10331498. S2CID 1498303.
Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, et al. (July 1999). "BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator". Science. 285 (5425): 260–263. doi:10.1126/science.285.5425.260. PMID 10398604.
Crowley JE, Treml LS, Stadanlick JE, Carpenter E, Cancro MP (June 2005). "Homeostatic niche specification among naïve and activated B cells: a growing role for the BLyS family of receptors and ligands". Seminars in Immunology. 17 (3): 193–199. doi:10.1016/j.smim.2005.02.001. PMID 15826824.
Edwards BM, Barash SC, Main SH, Choi GH, Minter R, Ullrich S, et al. (November 2003). "The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS". Journal of Molecular Biology. 334 (1): 103–118. doi:10.1016/j.jmb.2003.09.054. PMID 14596803.
Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, et al. (November 2003). "Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator". Arthritis and Rheumatism. 48 (11): 3253–3265. doi:10.1002/art.11299. PMID 14613291.
Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. (BLISS-52 Study Group) (February 2011). "Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial". Lancet. 377 (9767): 721–731. doi:10.1016/S0140-6736(10)61354-2. PMID 21296403. S2CID 28952240. Archived from the original on 17 October 2012. Retrieved 31 October 2012.
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al. (BLISS-76 Study Group) (December 2011). "A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus". Arthritis and Rheumatism. 63 (12): 3918–3930. doi:10.1002/art.30613. PMC 5007058. PMID 22127708.
Lee YH, Song GG (January 2018). "Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials". Lupus. 27 (1): 112–119. doi:10.1177/0961203317713143. PMID 28592201. S2CID 26026994.
Hahn BH (April 2013). "Belimumab for systemic lupus erythematosus". The New England Journal of Medicine. 368 (16): 1528–1535. doi:10.1056/NEJMct1207259. PMID 23594005.
Vugmeyster Y, Seshasayee D, Chang W, Storn A, Howell K, Sa S, et al. (February 2006). "A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys". The American Journal of Pathology. 168 (2): 476–489. doi:10.2353/ajpath.2006.050600. PMC 1606502. PMID 16436662.
Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, et al. (ATAMS Study Group) (April 2014). "Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial". The Lancet. Neurology. 13 (4): 353–363. doi:10.1016/S1474-4422(14)70028-6. PMID 24613349. S2CID 38926361.

ncbi.nlm.nih.gov

Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al. (BLISS-76 Study Group) (December 2011). "A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus". Arthritis and Rheumatism. 63 (12): 3918–3930. doi:10.1002/art.30613. PMC 5007058. PMID 22127708.
Vugmeyster Y, Seshasayee D, Chang W, Storn A, Howell K, Sa S, et al. (February 2006). "A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys". The American Journal of Pathology. 168 (2): 476–489. doi:10.2353/ajpath.2006.050600. PMC 1606502. PMID 16436662.

dailymed.nlm.nih.gov

"Benlysta- belimumab injection, powder, lyophilized, for solution Benlysta- belimumab solution". DailyMed. 17 January 2020. Archived from the original on 25 September 2020. Retrieved 29 July 2020.

nytimes.com

prescriptions.blogs.nytimes.com

Andrew Pollack, "F.D.A. Approves Benlysta, a New Lupus Drug" Archived 12 November 2020 at the Wayback Machine, The New York Times, 9 March 2011

nytimes.com

Pollack A (16 November 2010). "Benlysta, Lupus Treatment, Endorsed by F.D.A." The New York Times. Archived from the original on 9 November 2020. Retrieved 29 July 2020.

semanticscholar.org

api.semanticscholar.org

Shu HB, Hu WH, Johnson H (May 1999). "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens". Journal of Leukocyte Biology. 65 (5): 680–683. doi:10.1002/jlb.65.5.680. PMID 10331498. S2CID 1498303.
Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. (BLISS-52 Study Group) (February 2011). "Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial". Lancet. 377 (9767): 721–731. doi:10.1016/S0140-6736(10)61354-2. PMID 21296403. S2CID 28952240. Archived from the original on 17 October 2012. Retrieved 31 October 2012.
Lee YH, Song GG (January 2018). "Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials". Lupus. 27 (1): 112–119. doi:10.1177/0961203317713143. PMID 28592201. S2CID 26026994.
Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, et al. (ATAMS Study Group) (April 2014). "Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial". The Lancet. Neurology. 13 (4): 353–363. doi:10.1016/S1474-4422(14)70028-6. PMID 24613349. S2CID 38926361.

tga.gov.au

"BENLYSTA (GlaxoSmithKline Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 11 November 2022. Retrieved 15 April 2023.

the-rheumatologist.org

"FDA Approves Belimumab & Voclosporin for Lupus Nephritis". The Rheumatologist. 24 March 2021. Archived from the original on 5 May 2021. Retrieved 3 May 2021.

thelancet.com

Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. (BLISS-52 Study Group) (February 2011). "Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial". Lancet. 377 (9767): 721–731. doi:10.1016/S0140-6736(10)61354-2. PMID 21296403. S2CID 28952240. Archived from the original on 17 October 2012. Retrieved 31 October 2012.

unil.ch

serval.unil.ch

Bossen C, Schneider P (October 2006). "BAFF, APRIL and their receptors: structure, function and signaling" (PDF). Seminars in Immunology. 18 (5): 263–275. doi:10.1016/j.smim.2006.04.006. PMID 16914324.
Schneider P (June 2005). "The role of APRIL and BAFF in lymphocyte activation". Current Opinion in Immunology. 17 (3): 282–289. doi:10.1016/j.coi.2005.04.005. PMID 15886118.

web.archive.org

"Belimumab (Benlysta) Use During Pregnancy". Drugs.com. 5 February 2020. Archived from the original on 4 December 2020. Retrieved 29 July 2020.
"Benlysta- belimumab injection, powder, lyophilized, for solution Benlysta- belimumab solution". DailyMed. 17 January 2020. Archived from the original on 25 September 2020. Retrieved 29 July 2020.
"Benlysta EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 25 October 2020. Retrieved 29 July 2020.
Belimumab: The first drug to be FDA approved for the treatment of lupus since 1955 Archived 13 September 2021 at the Wayback Machine, By Rebecca Manno, Johns Hopkins Arthritis Center, 15 July 2011
European Medicines Agency: Benlysta Summary of Product Characteristics Archived 18 June 2018 at the Wayback Machine
"GlaxoSmithKline and Human Genome Sciences announce FDA approval of Benlysta (belimumab) for the treatment of systemic lupus erythematosus". GlaxoSmithKline. 9 March 2011. Archived from the original on 17 March 2011. Retrieved 11 March 2011.
"Benlysta (belimumab)". Human Genome Sciences. Archived from the original on 21 April 2011. Retrieved 11 March 2011.
"Human Genome Sciences And Glaxosmithkline Announce Initiation Of Phase 3 Clinical Trial Of Lymphostat-B In Systemic Lupus Erythematosus" (Press release). Human Genome Sciences. 13 February 2007. Archived from the original on 25 April 2011. Retrieved 11 March 2011.
Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. (BLISS-52 Study Group) (February 2011). "Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial". Lancet. 377 (9767): 721–731. doi:10.1016/S0140-6736(10)61354-2. PMID 21296403. S2CID 28952240. Archived from the original on 17 October 2012. Retrieved 31 October 2012.
FDA Questions Safety, Efficacy of Belimumab Archived 3 March 2021 at the Wayback Machine, By Emily P. Walker, Washington Correspondent, MedPage Today, 12 November 2010
Summary Minutes of the Arthritis Advisory Committee Meeting November 16, 2010 Archived 4 March 2017 at the Wayback Machine U.S. Food and Drug Administration (FDA)
2010 Meeting Materials, Arthritis Advisory Committee Archived 29 March 2012 at the Wayback Machine U.S. Food and Drug Administration (FDA)
Andrew Pollack, "F.D.A. Approves Benlysta, a New Lupus Drug" Archived 12 November 2020 at the Wayback Machine, The New York Times, 9 March 2011
"Should Belimumab Have Been Approved? Stephen Paget, Medscape Rheumatology, Mar 24, 2011". Archived from the original on 16 November 2015. Retrieved 27 April 2013.
"Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome (BELISS)". July 2012. Archived from the original on 18 October 2012. Retrieved 1 November 2012.
"FDA Approves Belimumab & Voclosporin for Lupus Nephritis". The Rheumatologist. 24 March 2021. Archived from the original on 5 May 2021. Retrieved 3 May 2021.
"FDA approves Benlysta to treat lupus" (Press release). U.S. Food and Drug Administration (FDA). 9 March 2011. Archived from the original on 11 March 2011.
Pollack A (16 November 2010). "Benlysta, Lupus Treatment, Endorsed by F.D.A." The New York Times. Archived from the original on 9 November 2020. Retrieved 29 July 2020.
"Benlysta granted Orphan Drug Designation by US FDA for the potential treatment of systemic sclerosis". GSK (Press release). Archived from the original on 9 February 2023. Retrieved 9 February 2023.
"GSK Says Benlysta Granted Orphan Drug Designation By FDA". MarketScreener. February 2023. Archived from the original on 9 February 2023. Retrieved 9 February 2023.
HGSI Cuts Loss on Benlysta Sales Archived 7 April 2019 at the Wayback Machine, By Zacks Equity Research, 26 April 2012
NICE publishes draft guidance on belimumab for systemic lupus erythematosus Archived 12 September 2012 at the Wayback Machine, press release, 26 April 2012

yahoo.com

finance.yahoo.com

HGSI Cuts Loss on Benlysta Sales Archived 7 April 2019 at the Wayback Machine, By Zacks Equity Research, 26 April 2012